Drugs / LBVH0101
last change Mar 2009 re-read 2 minutes ago

LBVH0101

Vaccine

Developed for
haemophilus infectious disease
Investigated by
LG Life Sciences

Trials 2 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01251133 Jul 2008 → Mar 2009 haemophilus infectious disease LG Life Sciences Completed No outcome recorded
Phase 3 NCT01019772 Jul 2007 → Aug 2008 haemophilus infectious disease LG Life Sciences Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as LBVH0101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01251133
1

NCT01019772

Modality Vaccine “LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine)” NCT01019772